John Gevisser Assumes MedX Health’s Corner Office

MedX Health Corp. has appointed John Gevisser as CEO, effective immediately.

Gevisser previously was the chief digital officer at Health Partners Group, the United Kingdom’s largest provider of occupational health services, where he led the company’s technology and data strategy. He also supervised strategic partnerships and operationalized MedX’s U.K. pilot programs. Before that, he served as vice president of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality’s direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world’s largest wellness platform.

“John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX’s operations,” said Mike Druhan, MedX president of Dermatology Services. “His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.”

As MedX’s CEO, Gevisser will focus on expanding MedX’s international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities.

“Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,” Gevisser stated. “As a former client, I saw firsthand how seamlessly MedX’s hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its solution to at-risk patients in the workplace is gaining market acceptance.”

While passing the CEO role to Gevisser, former chief executive Stephen Lockyer will remain as president of MedX. “The board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a director, CEO, and president in 2023 and has been a very significant contributor to the development and advances made by the company since that time,” MedX Board Chairman Ken McKay commented.

Headquartered in Ontario, Canada, MedX Health Corp. provides non-invasive skin assessment and teledermatology solutions. Its proprietary SIAscopy technology, integrated into the DermSecure platform, enables pain-free, accurate skin lesion imaging for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the United States, Australia, New Zealand, the United Kingdom, the European Union, and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure. SIAscopy is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin’s surface.